Gonzalo Alberto Peralta-Jiménez
Research Subjects
Research Interests
Gonzalo Alberto Peralta-Jiménez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Vera-Calzaretta
Universidad de Atacama, Chile
1 shared publication - Carolina Alexandra Adelina Chambi-Martínez
Facultad de Medicina, Universidad de Concepción, Concepción, Chile
1 shared publication - Darío Páez
Facultad de Educación y Humanidades Universidad Andres Bello, Santiago, Chile. Centro de Investigación, Innovación y Creación, Universidad Catolica de Temuco
1 shared publication - Esteban Iván Moraga-Escobar
Programa de Neurociencia, Psiquiatría y Salud Mental, NEPSAM (http://nepsam.udec.cl), Universidad de Concepción, Barrio Universitario s/n, Casilla 160-C, Concepción 4070386, Chile
1 shared publication - Gonzalo Klaassen P.
Departamento de Especialidades, Facultad de Medicina, Universidad de Concepción, Concepción, Chile
1 shared publication - Jaime Barrientos
Universidad Alberto Hurtado
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 2493-2506
Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Purpose: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin’s potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM). Methods: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher’s Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model. Results: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69– 2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher’s Z = 0.4; 95% CI: 0.240– 0.554, p < 0.001) and body mass index (BMI) (Fisher’s Z = 0.17; 95% CI: 0.036– 0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher’s Z = − 0.35; 95% CI: − 0.471 to − 0.239, p < 0.001). Conclusion: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.
- 1 July 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 2493-2506
Open AccessAsprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Purpose: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin’s potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM). Methods: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher’s Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model. Results: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69– 2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher’s Z = 0.4; 95% CI: 0.240– 0.554, p < 0.001) and body mass index (BMI) (Fisher’s Z = 0.17; 95% CI: 0.036– 0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher’s Z = − 0.35; 95% CI: − 0.471 to − 0.239, p < 0.001). Conclusion: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.
- 21 December 2021
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 34 (2) , 277-290
Social Support, Stress and Emotional Symptoms Among LGBTQ+ College Students in Chile
To compare the relationships between emotional symptomatology and perceived social support according to gender identity and sexual orientation in LGBTQ+ university students.322 Chilean LGBTQ+ colle...
- 21 December 2021
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 34 (2) , 277-290
Social Support, Stress and Emotional Symptoms Among LGBTQ+ College Students in Chile
To compare the relationships between emotional symptomatology and perceived social support according to gender identity and sexual orientation in LGBTQ+ university students.322 Chilean LGBTQ+ colle...